Welcome to AI Meets Life Sci, the newest video podcast from DeviceTalks and Drug Discovery & Development. Co-hosted by Kayleen Brown, managing editor at DeviceTalks, and Brian Buntz, pharma and biotech editor, the series offers a comprehensive look into the intersection of AI and life sciences from two unique perspectives.

WATCH the episode on Youtube - https://youtu.be/yW1fbtLoVg0
READ a TL;DR and deep-dive article - https://www.drugdiscoverytrends.com/can-ai-move-fast-and-cure-things-in-healthcare/

In the first segment, Paul Friedman, MD, Chair of the Department of Cardiovascular Medicine at Mayo Clinic, and Dave McMullin, Chief Business Officer of Anumana, discuss the groundbreaking collaboration between Mayo Clinic and Anumana in applying AI to enhance cardiovascular diagnostics, particularly through ECGs. They explore how AI can detect cardiac conditions early, with a focus on the EAGLE study's findings on AI-enhanced ECGs, and discuss Anumana's role in transforming these AI innovations into accessible medical devices.

In the second segment, Jeff Elton, PhD, CEO of ConcertAI, speaks to the transformative role of AI in clinical trials. He sheds light on AI's capabilities in improving patient selection for clinical trials and streamlining processes within life sciences. Dr. Elton emphasizes the broader implications of AI, from enhancing patient care to accelerating the development of new treatments, and discusses the ethical considerations of AI integration in healthcare.These interviews provide insights into the evolving roles of AI in various sectors like medtech, pharma, and biotech, showcasing its potential in transforming healthcare and research methodologies.

But that's not all! Join us for the next episode of AI Meets Life Sci, which features an interview with the Global Business Leader for Health and Life Sciences at Microsoft.

Catch the full episode on major podcast platforms and YouTube to dive deeper into the exciting convergence of AI and healthcare.

Thank you to our contributors, some of who include Catalyze Healthcare and SmartTRAK Business Intelligence, for providing vital support. To learn more about our contributors, visit: www.catalyzehealthcare.com and www.smarttrak.com.

Thank you for watching and listening to AI Meets Life Sci.

Mayo Clinic & Anumana transform ECG with AI; ConcertAI dishes on next-gen trials

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.
https://scrip.citeline.com/SC149413/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip’s Five Must-Know Things – 27 November 2023

Every year on 1st December, we mark World AIDS Day to show solidarity in the fight against HIV and AIDS, and to remember those who have sadly lost their lives.  

Since the start of the global AIDS epidemic in the 1980s, researchers have made enormous progress towards preventing HIV transmission, and treating those who are living with HIV so that the virus remains suppressed. But while there have been marked improvements for adults, treatment coverage in children and adolescents is lagging behind.  

In the first of our World AIDS Day episodes, Dr Anna Turkova, Clinical Principal Research Fellow at the MRC Clinical Trials Unit at UCL, and Philippa Musoke, Professor of Paediatrics and Child Health at Makerere University, explore the reasons for these disparities and how the MRC CTU at UCL is working to close the gap between adults and children through clinical trials.   

For more information and to access the transcript: https://www.mrcctu.ucl.ac.uk/news/news-stories/2023/december/trial-talk-podcast-releases-new-episodes-for-world-aids-day/

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk 

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

World AIDS Day (part 1): Closing the gap between adults and children

Every year on 1st December, we mark World AIDS Day to show solidarity in the fight against HIV and AIDS, and to remember those who have sadly lost their lives.  

Since the start of the global AIDS epidemic in the 1980s, researchers have made enormous progress towards preventing HIV transmission, and treating those who are living with HIV so that the virus remains suppressed. But while there have been marked improvements for adults, treatment coverage in children and adolescents is lagging behind. 

In the second of our World AIDS Day episodes, we highlight the important role that young people living with HIV play in research, by shaping clinical trials to better serve the needs of their community.  

This episode features Lungile Jafta, who works closely with young people through Penta’s youth engagement programmes, and Gugu, a former Youth Trials Board member from South Africa who is living with HIV. 

For more information and to access the transcript: https://www.mrcctu.ucl.ac.uk/news/news-stories/2023/december/trial-talk-podcast-releases-new-episodes-for-world-aids-day/

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk 

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

World AIDS Day (part 2): Bringing hope through research to young people living with HIV

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.
https://scrip.citeline.com/SC149443/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 4 December 2023

This episode of VHHA's Patients Come First podcast features an interview Dr. Nassima Ait-Daoud Tiouririne, the director of UVA’s Center for Leading Edge Addiction Research, for a conversation about her work to support individuals with substance use disorder, research and clinical trials on addiction, and more. Send questions, comments, feedback, or guest suggestions to pcfpodcast@vhha.com or contact us on Twitter (twitter.com/VirginiaHHA) or Instagram (www.instagram.com/virginiahha/) using the #PatientsComeFirst hashtag.

VHHA Patients Come First Pocast - Dr. Nassima Ait-Daoud Tiouririne

Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down for an engaging podcast interview with Dr. Ari VanderWalde, Global Head of Clinical Trials at Caris Life Sciences. Join them as they delve into the world of clinical trials, exploring the intricacies of clinical research, providing valuable insights into Caris' contributions, and the accessibility of these transformative opportunities.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. Ari VanderWalde - Clinical Trials at Caris Life Sciences: The Path Forward

Uncover the path to equitable clinical trials in the latest Caris Molecular Minute podcast with host Dr. Chadi Nabhan, Chairman of the Caris Precision Oncology Alliance and his guest, Dr. Ishwaria Subbiah, Executive Director at Sarah Cannon Research Institute. Together, they explore ways to enhance patient access and enrollment, mitigate disparities, and foster equality in clinical trials. Don't miss this thought-provoking conversation aimed at reshaping the narrative for a more inclusive and impactful future in cancer care and research.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. Ishwaria Subbiah: Equity in Clinical Trials

This episode of AI Meets Life Sci explores the potential for data-driven innovation in healthcare, through conversations with leaders at Microsoft and 1910 Genetics.

In the first segment, Elena Bonfiglioli, Global Business Leader for Healthcare, Pharma and Life Sciences at Microsoft, discusses the significance of computation, an essential element of AI investments, in enhancing R&D productivity in healthcare. She emphasizes the need for new approaches to drug development, including shorter clinical trial timelines and the shift toward more efficient R&D. Bonfiglioli also highlights the importance of multimodal data in research and development. In addition, speaks to the integral role of computational methods in drug development, emphasizing how they augment our disease understanding and clinical trial design.

In the second segment, Jen Nwankwo, PhD, Founder & CEO of 1910 Genetics - a Y Combinator and Sam Altman-backed startup, shares the innovation strategies around drug discovery. She details their problem-first approach, leading to an integrated, modality-agnostic drug discovery tech stack. Dr. Nwankwo highlights the use of Azure Quantum Elements in accelerating molecular simulations, positioning 1910 Genetics uniquely in designing both small and large molecules. Their global approach to accessible drug discovery through strategic partnerships is emphasized.

Join us for the next episode of AI Meets Life Sci, featuring an exclusive interview with Ben Newton, Chief Digital Officer and GM of Oncology at GE Healthcare.

Thank you to our contributors, some of whom include Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.

Tune in and subscribe to AI Meets Life Sci on all major podcast channels and follow youtube.com/@DeviceTalks or AI Meets Life Sci YouTube Podcast to ensure you never miss an episode.

WATCH, LISTEN, and READ. Thank you for supporting AI Meets Life Sci!

Read Now: www.drugdiscoverytrends.com/microsoft-1910-genetics-data-hidden-gems

The episode where we discover data’s hidden gems with Microsoft and Sam Altman-backed 1910 Genetics

This episode of AI Meets Life Sci explores the potential for data-driven innovation in healthcare, through conversations with leaders at Microsoft and 1910 Genetics.

In the first segment, Elena Bonfiglioli, Global Business Leader for Healthcare, Pharma and Life Sciences at Microsoft, discusses the significance of computation, an essential element of AI investments, in enhancing R&D productivity in healthcare. She emphasizes the need for new approaches to drug development, including shorter clinical trial timelines and the shift toward more efficient R&D. Bonfiglioli also highlights the importance of multimodal data in research and development. In addition, speaks to the integral role of computational methods in drug development, emphasizing how they augment our disease understanding and can help with clinical trial design.

In the second segment, Jen Nwankwo, PhD, Founder & CEO of 1910 Genetics - a Y Combinator and Sam Altman-backed startup, shares the innovation strategies around drug discovery. She details their problem-first approach, leading to an integrated, modality-agnostic drug discovery tech stack. Dr. Nwankwo highlights the use of Azure Quantum Elements in accelerating molecular simulations, positioning 1910 Genetics uniquely in designing both small and large molecules. Their global approach to accessible drug discovery through strategic partnerships is emphasized.

Join us for the next episode of AI Meets Life Sci, featuring an exclusive interview with Ben Newton, Chief Digital Officer and GM of Oncology at GE Healthcare.

Thank you to our contributors, some of whom include Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.
Tune in and subscribe to AI Meets Life Sci on all major podcast channels and follow youtube.com/@DeviceTalks or AI Meets Life Sci YouTube Podcast to ensure you never miss an episode. 

WATCH, LISTEN, and READ: https://linktr.ee/AIMeetsLifeSci. Thank you for supporting AI Meets Life Sci!

Read Now: www.drugdiscoverytrends.com/microsoft-1910-genetics-data-hidden-gems

Discovering data’s hidden gems with Microsoft and Sam Altman-backed 1910 Genetics

In this podcast Scrip looks at the some upcoming clinical catalysts for biopharma, judged by the size of the sales forecasts at stake. Companies including Sanofi, Cytokinetics, Corcept and Inventiva stand to gain – or lose.

Biopharma’s Must-Know 2023-4 Catalysts

In this episode, Dr. Paul Wheatley-Price sits down with Dr. Vishal Navani, Medical Oncologist at the Tom Baker Cancer Centre, and Dr. Andrea Fung, Thoracic Medical Oncologist in Kingston Health Sciences Centre. They chat about the latest developments in lung cancer research at the 2023 ESMO conference in Madrid, Spain this past October.

Best Of ESMO 2023

This episode of AI Meets Life Sci emphasizes the prognostic and point-of-care decision-making power of AI in oncology while addressing real-world implementation issues from regulation and liability to clinician trust and adoption, through conversations with leaders at GE HealthCare and Catalyze Healthcare.

In the first segment, Ben Newton, General Manager of Oncology at GE HealthCare describes likely future advances in multimodal computing, which could parse diverse datasets from pathology, imaging, genomics and other domains to predict likely outcomes in given treatment scenarios. Newton also emphasized AI's ability to help overwhelmed physicians by alleviating workflow bottlenecks and assisting with point-of-care decision making. Despite the promise, he underscored that such advances rely on incorporating clinicians’ valuable perspective when developing these AI systems and partnerships with other industry stakeholders, such as cloud partners like AWS and academic centers or hospitals, to access data and create foundation models.

In the second segment, Haley Schwartz, CEO at Catalyze Healthcare, highlights the potential of using AI for screening applications as an initial stepping stone to build trust and adoption. She also notes that potential headwinds for hospital adoption of AI are questions related to legal liability and reimbursement impacts. In addition, Schwartz emphasizes the importance of physician involvement, especially during the early stages of AI integration into healthcare.

Join us for the next episode of AI Meets Life Sci, featuring a keynote interview with Helen Merianos, Head of Sanofi’s R&D Portfolio Strategy.

Thank you to our contributors, some of whom include Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.Tune in and subscribe to AI Meets Life Sci on all major podcast channels and follow youtube.com/@DeviceTalks or AI Meets Life Sci YouTube Podcast to ensure you never miss an episode.

WATCH, LISTEN, and READ. Thank you for supporting AI Meets Life Sci!

Read Now:
Watch Now: https://youtu.be/XtGbJ-2Jyro

GE HealthCare pulls back the curtain on its unmatched AI clearances; Catalyze tackles AI trust gap

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: the biggest drug launches expected in 2024; Roche’s Pharma CEO talks about growth momentum; 10 pivotal studies to look out for this year; the obesity market now and in future; and what does 2024 hold for transformative technology in biopharma.

https://scrip.citeline.com/SC149742/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 5 February 2024

BUFFALO, NY- February 5, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on January 24, 2024, entitled, “The fate of drug discovery in academia; dumping in the publication landfill?”

In this new editorial, researchers Uzma Saqib, Isaac S. Demaree, Alexander G. Obukhov, Mirza S. Baig, Amiram Ariel, and Krishnan Hajela, from Devi Ahilya Vishwavidyalaya, Indore, discuss drug discovery—a tedious process that is time consuming in both divulging whether a molecule is efficacious and specific in hitting the target and also in confirming that the potential drug does not cause severe adverse effects. Many drug candidates fail crossing multiple checkpoints of this long journey; they lag in one or several aspects and never move beyond the research bench to contribute to public health. These setbacks make the process of drug discovery very time consuming, expensive, and tedious. 

“This viewpoint is focused on delineating how and why the multi-million [dollar] research efforts in the field of drug discovery often fail to reach its full potential.”

There is no shortage of studies focusing on drug discovery. They are published on a daily basis describing the efforts encompassing conventional and/or modern drug discovery technology, including structure-based drug design (SBDD), virtual screening, high-throughput screening (HTS), Artificial Intelligence (AI), and cell-based screening approaches (Figure 1). However, many drug development strategies are rather fuzzy in their advancement. 

Thus, there is a large gap between drug “discovery” and “development.” This part could be attributed to the lack of synergy between Academia and Industry at multiple levels. A significant part of this failure results from the lack of streamlining of drug development process. 

“In the current perspective, we discussed why many therapeutic molecules never make it to clinical studies despite being proven efficacious pre-clinically. Additionally, we discussed the possible solutions to overcome this défaut of the drug development process.”

DOI - https://doi.org/10.18632/oncotarget.28552

Correspondence to - Krishnan Hajela - hajelak@gmail.com

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28552

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, drug discovery and development, clinical trials, academia-industry collaboration, translational research, drug database

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Oncotarget

Drug Discovery in Academia; Dumping in the Publication Landfill?

BUFFALO, NY- February 7, 2024 – A new #research perspective was #published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

In this new paper, researchers Ashley Del Dosso, Elizabeth Tadevosyan, and James R. Berenson from ONCOtherapeutics, Berenson Cancer Center, and Institute for Myeloma and Bone Cancer Research discussed multiple myeloma (MM) — the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. 

In recent years, new and more effective drugs have become available for the treatment of this B-cell malignancy. These new drugs have often been evaluated together and in combination with older agents. However, even these novel combinations eventually become ineffective; and, thus, novel therapeutic approaches are necessary to help overcome resistance to these treatments. 

Recently, the Janus Kinase (JAK) family of tyrosine kinases, specifically JAK1 and JAK2, has been shown to have a role in the pathogenesis of MM. Preclinical studies have demonstrated a role for JAK signaling in direct and indirect growth of MM and downregulation of anti-tumor immune responses in these patients. Also, inhibition of JAK proteins enhances the anti-MM effects of other drugs used to treat MM. These findings have been confirmed in clinical studies which have further demonstrated the safety and efficacy of JAK inhibition as a means to overcome resistance to currently available anti-MM therapies. Additional studies will provide further support for this promising new therapeutic approach for treating patients with MM.

“The following sections of this article will be focused on studies of RUX [Ruxolitinib] in the preclinical [21–24] and clinical settings [18–20] focused on the treatment of relapsed/refractory (RR) MM.”

DOI - https://doi.org/10.18632/oncotarget.28547

Correspondence to - James R. Berenson - jberenson@berensoncancercenter.com

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28547

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, multiple myeloma, ruxolitinib, JAK/STAT, cytokine, clinical trial

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma

This episode of AI Meets Life Sci offers a comprehensive look at the ways AI is poised to upend the pharmaceutical industry. It features an in-depth keynote interview with Helen Merianos, Head of Sanofi's R&D Portfolio Strategy, who provides an inside look into Sanofi's commitment to go "all-in" on AI and data science. Merianos discusses the use of Sanofi's proprietary plai app – an AI-enabled smartphone app that draws from over a billion data points – and its role in establishing a data-driven culture across the company.

Additionally, the episode features Michelle Longmire, MD, Co-Founder and CEO of Medable, who discusses the use of generative AI in automating and accelerating clinical trial technology deployment timelines. These applications could cut some timelines in half. Longmire envisions AI's potential to drastically accelerate a development process. “Say there's 10,000 uncured or poorly suboptimally treated human diseases.” At the current pace of drug development, it might take about 200 years to create treatments for those conditions. “Imagine if we could 10x that,” Longmire says.

Join us for the next episode of AI Meets Life Sci, where we sit down with Ha Hong, PhD, Chief Artificial Intelligence Officer, Endoscopy at Medtronic.

Thank you to our sponsors Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.
catalyzehealthcare.com
smarttrak.com

Tune in and subscribe to AI Meets Life Sci on all major podcast channels and follow youtube.com/@DeviceTalks or AI Meets Life Sci YouTube Podcast to ensure you never miss an episode.

WATCH, LISTEN, and READ: https://www.drugdiscoverytrends.com/when-will-drug-development-have-its-chatgpt-moment-inside-ambitious-ai-initiatives-at-sanofi-and-medable/

Thank you for supporting AI Meets Life Sci!

Sanofi races to the AI forefront in Big Pharma; Plus, Medable's big promises for clinical trials

This episode of AI Meets Life Sci offers a comprehensive look at the ways AI is poised to upend the pharmaceutical industry. It features an in-depth keynote interview with Helen Merianos, Head of Sanofi's R&D Portfolio Strategy, who provides an inside look into Sanofi's commitment to go "all-in" on AI and data science. Merianos discusses the use of Sanofi's proprietary plai app – an AI-enabled smartphone app that draws from over a billion data points – and its role in establishing a data-driven culture across the company.

Additionally, the episode features Michelle Longmire, MD, Co-Founder and CEO of Medable, who discusses the use of generative AI in automating and accelerating clinical trial technology deployment timelines. These applications could cut some timelines in half. Longmire envisions AI's potential to drastically accelerate a development process. “Say there's 10,000 uncured or poorly suboptimally treated human diseases.” At the current pace of drug development, it might take about 200 years to create treatments for those conditions. “Imagine if we could 10x that,” Longmire says.

Join us for the next episode of AI Meets Life Sci, where we sit down with Ha Hong, PhD, Chief Artificial Intelligence Officer, Endoscopy at Medtronic.

Thank you to our sponsors Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.
catalyzehealthcare.com
smarttrak.com

Tune in and subscribe to AI Meets Life Sci on all major podcast channels and follow youtube.com/@DeviceTalks or AI Meets Life Sci YouTube Podcast to ensure you never miss an episode.

WATCH, LISTEN, and READ. Thank you for supporting AI Meets Life Sci!

Meet Dr. Ezra Cohen, a medical oncologist and cancer researcher based in San Diego. He is organizing clinical and research studies on various cancers at Tempus. In this episode of the Project Purple Podcast, Ezra explains the scientific reasoning behind different cancers and tumors, and how they respond to treatment methods such as immunotherapy, radiation, and chemotherapy. 

Additionally, Ezra talks about his groundbreaking artificial intelligence work at Tempus, which aims to make clinical trials more accessible and easier to navigate for patients undergoing cancer treatment. He also discusses how this technology has contributed to researching other cancers like pediatric leukemia and how it is used to study pancreatic cancer. 

Join us for this informative and insightful episode of the Project Purple Podcast to learn more about the clinical trial matching system Tempus offers, and how it can benefit patients seeking cancer treatment.

If you’d like to donate to Project Purple’s mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/.

If you would like to stay up to date with the latest strides that Tempus has made in the cancer space, or to see the clinical trial available to you, visit: 
https://www.tempus.com/ 

To learn more about Project Purple, visit https://www.projectpurple.org/ or follow us on social media at these links:
https://www.facebook.com/Run4ProjectPurple 
https://www.instagram.com/projectpurple/ 
https://twitter.com/Run4Purple 
https://www.youtube.com/channel/UCgA8nVhUY6_MLj5z3rnDQZQ

Episode 276 - Fighting to Save Lives with Dr. Ezra Cohen, MD

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

AI Meets Life Sci explores the transformative role of AI and ML in the life sciences. The series zeroes in on major obstacles and opportunities in healthcare, presenting insights from Big Pharma, medtech OEMs, and Tech Giants, shaping the healthcare landscape and leading to better health outcomes. 

#medtech #pharma #technology #artificialintelligence #ai #machinelearning #videopodcast #podcast #medicaltechnology #pharmaceutical 

This video podcast is powered by DeviceTalks and is a collaboration between DeviceTalks and Drug Discovery & Development. Co-Hosts: Kayleen Brown, Managing Editor, DeviceTalks and Brian Buntz, Pharma Editor, Drug Discovery & Development. 

www.devicetalks.com/AI

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

The Trial Talk podcast explores how our work at the MRC Clinical Trials Unit at UCL is improving health in the UK and worldwide. In this series, we hear from world-leading experts about the studies we carry out. We delve into trials on cancer, infections and neurodegenerative diseases, explore how public and patient involvement shapes our work, and discover new ways to run smarter studies.

Project Purple's vision is a world without pancreatic cancer. We have two initiatives: to help pancreatic cancer patients and fund research. With a variety of partners in the health and fitness world, our podcast will deliver an exciting look into our own background as well as the worlds of medical treatment, marathon running, crossfit, nutrition, stories of survival, inspiration, hope, and much more.

The DeviceTalks Podcast Network delivers news, insights and commentary from Medtech industry leaders. Our podcasts will inspire medtech professionals to create better medtech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 8 podcasts:

• AbbottTalks
• AI Meets Life Sci
• Boston Scientific Talks
• DeviceTalks Weekly
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

Lung Cancer Canada is Canada's only national charitable organization focused solely on lung cancer

New tracks tagged #Clinicaltrials